Cambridge Cognition Partners With Ivory to Scale Early Cognitive Screening With CANTAB Pathway™ in India
Highlights
-
Ivory will deploy CANTAB Pathway™ across both professional healthcare and consumer health segments in
India - Of India’s population of approximately 1.47 billion, estimates indicate that 138 million people are aged over 60, and as many as 34 million may be living with mild or major cognitive impairment
- India’s middle and affluent class, estimated to be 90-190 million people, is believed to have an increasing interest in longevity, healthspan, and access to high-quality healthcare
This partnership represents an important strategic step in Cambridge Cognition’s expansion into high-growth international healthcare and consumer markets, leveraging Ivory’s rapidly scaling brain health platform and distribution network.
India represents a significant growth opportunity with a population of approximately 1.47 billion. Recent research estimated that among India’s 138 million people aged over 60, as many as 34 million may be living with mild or major cognitive impairment (Gross et al., PLOS One, LASI-DAD study).
We believe the Ivory team shares our passion and energy to make a difference and has made impressive progress across both consumer and professional healthcare markets. We are excited to partner with them to expand access to CANTAB Pathway™ in
Ivory recently published India’s first-of-its-kind Brain Health Report, providing new insights into the country’s cognitive wellbeing landscape. Multiple studies suggest that up to 90% of cognitive impairment remains underdiagnosed, highlighting a substantial unmet need for scalable early screening solutions.
With no definitive cure for neurodegenerative conditions like dementia, prevention and early identification are increasingly critical. Ivory’s mission is to shift the focus from late-stage diagnosis to proactive brain health management through neuroscience-based digital assessments, enabling individuals to take action before symptoms escalate.
India has an expanding middle and affluent class, with an estimated 90-190 million people for whom longevity, healthspan, and access to high-quality healthcare are growing priorities. In parallel, younger urban populations are increasingly tech-enabled and motivated to manage their health through monitoring and lifestyle choices.
Dr. Sumiti Saharan, Chief Scientific Officer, Ivory, said “Early cognitive screening is one of the most powerful ways to change trajectories in neurodegenerative conditions, where intervention often begins only after cognitive decline has already advanced. In India, under diagnosis of cognitive impairment remains a significant gap. Scalable, validated digital tools such as CANTAB Pathway™ offer an opportunity to standardise assessment, enable earlier identification and empower clinicians to intervene at a stage when it can make the greatest difference.”
This strategic partnership between
Under this agreement, Ivory intends to deploy CANTAB Pathway™ at scale across both professional healthcare and consumer health segments in
NOTES TO EDITORS
ABOUT
The Company has developed a suite of touchscreen and voice-based cognitive assessments delivered under the CANTAB and Winterlight brands. These assessments are designed to:
- require minimal specialist administration
- deliver objective results in real time or shortly after completion
- reduce administrator bias
- support longitudinal monitoring of cognitive function
Assessment results can be presented in formats appropriate for both consumers in home-use settings and healthcare professionals in clinical or research environments.
Most of Cambridge Cognition’s assessments are available in multiple languages. Relevant to the Ivory agreement, tasks are currently available in Hindi, Tamil, Telugu, Bengali and Kannada, with further language expansion under consideration.
CANTAB Pathway™ is Cambridge Cognition’s latest scalable cognitive assessment solution, structured as an escalating series of tasks for use in consumer and healthcare settings:
- CANTAB One™ – a brief assessment of overall cognitive function
- CANTAB Insight™ – a three-task battery providing deeper insight across five cognitive sub-domains
- CANTAB Plus™ – specialist disease-specific modules for use by appropriately qualified healthcare professionals, covering eight indications including Parkinson’s disease, ADHD, multiple sclerosis, Huntington’s disease, schizophrenia, depression, and Alzheimer’s disease and related dementias
For further information, visit: www.cambridgecognition.com
ABOUT IVORY
Founded in
Website link: https://www.liveivory.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20260217426778/en/
Enquiries:
Tel: +44 1223 810700
press@camcog.com
Ivory
Ivory Press Relations:
+91 885 019 3264
issac@liveivory.com
Tel: +44 20 7886 2968
(Corporate Finance)
(Corporate Broking)
Singer
Tel: +44 20 7496 3000
Source:
